BTIG analyst Thomas Catherwood downgrades Paramount Group (NYSE:PGRE) from Buy to Neutral.
Applied Therapeutics’ Diabetes-Associated Heart Disease Drug Fails In Phase 3 Study, Stock Plunges
Applied Therapeutics Inc (NASDAQ: APLT) released topline results of the ARISE-HF Phase 3 trial of AT-001 (caficrestat) in patients with Diabetic Cardiomyopathy (DbCM) at high risk of